Monograph
Phentermine/Topiramate (Qsymia) — Second-Line Anti-Obesity in the GLP-1 Era
Qsymia is a fixed-dose combination of immediate-release phentermine (a sympathomimetic appetite suppressant) and extended-release topiramate (an anticonvulsant with appetite-reducing properties through multiple mechanisms), FDA-approved in July 2012…
By Kristopher Crawford
·
30 May 2026
·
7 min read
Qsymia is a fixed-dose combination of immediate-release phentermine (a sympathomimetic appetite suppressant) and extended-release topiramate (an anticonvulsant with appetite-reducing properties through multiple mechanisms), FDA-approved in July 2012…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.